Institute for Complementary and Integrative Medicine, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Department of Biostatistics at the Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
JAMA Netw Open. 2021 Sep 1;4(9):e2121418. doi: 10.1001/jamanetworkopen.2021.21418.
In observational studies, patients' treatment outcome expectations have been associated with better outcomes (ie, a placebo response), whereas concerns about adverse side effects have been associated with an in increase in the negative effects of treatments (ie, a nocebo response). Some randomized trials have suggested that communication from clinicians could affect the treatment outcomes by changing patients' expectations.
To investigate whether treatment outcome expectations and reported adverse side effects could be affected by different briefing contents before a minimal acupuncture treatment in patients with chronic low back pain (CLBP).
DESIGN, SETTING, AND PARTICIPANTS: This randomized single-blinded clinical trial was conducted among patients with CLBP at 1 outpatient clinic in Switzerland who had a pain intensity of at least 4 on a numeric rating scale from 0 to 10. Different recruitment channels were used to enroll patients. Data were collected from May 2016 to December 2017 and were analyzed from June to November 2018.
Patients were randomized to receive either a regular expectation briefing or a high expectation briefing (effectiveness) and either a regular adverse side effect briefing or an intense adverse side effect briefing (adverse side effect) in a 2 × 2 factorial design. The intervention (briefing sessions and written materials) was standardized and delivered before the acupuncture treatment, with additional booster informative emails provided during the 4-week, 8-session acupuncture course.
The primary end point was the patients' expectations regarding the effectiveness of the acupuncture treatment (Expectation for Treatment Scale [ETS]) after the briefing and the subsequent pain intensity (numeric rating scale). The primary end point for the adverse side effect briefing was the adverse side effect score at the end of the acupuncture treatment, derived from session-by-session assessments of adverse side effects.
A total of 152 patients with CLBP (mean [SD] age, 39.54 [12.52] years; 100 [65.8%] women) were included. The estimated group difference (regular vs high) for the ETS was -0.16 (95% CI -0.81 to 0.50, P = .64), indicating no evidence for a difference between intervention groups. There was also no evidence for a difference in pain intensity at the end of the acupuncture treatment between the groups with different expectation briefings. The adverse side effects score in the group with the intense adverse side effect briefing were estimated to be 1.31 times higher (95% CI, 0.94 to 1.82; P = .11) than after a regular adverse side effect briefing, but the finding was not statistically significant.
In this study, suggestions regarding treatment benefits (placebo) and adverse side effects (nocebo) did not affect treatment expectations or adverse side effects. Information regarding adverse side effects might require more research to understand nocebo responses.
German Clinical Trials Register Identifier: DRKS00010191.
在观察性研究中,患者对治疗结果的预期与更好的结果(即安慰剂反应)有关,而对不良反应的担忧与治疗的负面影响增加(即反安慰剂反应)有关。一些随机试验表明,临床医生的沟通可以通过改变患者的期望来影响治疗结果。
研究不同的简要介绍内容是否会影响慢性下背痛(CLBP)患者接受最小化针刺治疗前后的治疗结果预期和报告的不良反应。
设计、地点和参与者:这是一项在瑞士一家门诊诊所进行的慢性下背痛患者的随机单盲临床试验,这些患者的疼痛强度至少为数字评定量表(NRS)上的 4 分(范围为 0 至 10)。使用了不同的招募渠道来招募患者。数据于 2016 年 5 月至 2017 年 12 月收集,并于 2018 年 6 月至 11 月进行分析。
患者以 2×2 析因设计随机分为常规效果预期介绍或高效果预期介绍(效果)以及常规不良反应介绍或强烈不良反应介绍(不良反应)。干预措施(介绍会和书面材料)是标准化的,并在针刺治疗前进行,在 4 周、8 次针刺疗程期间提供额外的强化信息电子邮件。
主要终点是患者在介绍后对针刺治疗效果(治疗效果期望量表 [ETS])的预期以及随后的疼痛强度(NRS)。不良反应介绍的主要终点是针刺治疗结束时的不良反应评分,该评分来自于对不良反应的逐次评估。
共有 152 名慢性下背痛患者(平均[标准差]年龄,39.54[12.52]岁;100[65.8%]名女性)被纳入研究。ETS 的估计组间差异(常规 vs 高)为-0.16(95%CI-0.81 至 0.50,P=0.64),表明干预组之间没有差异的证据。在接受不同期望介绍的组之间,针刺治疗结束时的疼痛强度也没有差异。接受强烈不良反应介绍的组的不良反应评分估计高出 1.31 倍(95%CI,0.94 至 1.82;P=0.11),但这一发现没有统计学意义。
在这项研究中,关于治疗益处(安慰剂)和不良反应(反安慰剂)的建议并未影响治疗预期或不良反应。关于不良反应的信息可能需要更多的研究来了解反安慰剂反应。
德国临床试验注册中心标识符:DRKS00010191。